Navigation Links
Experimental Biology 2008 Today's Research: Tomorrow's Health, April 5-9
Date:2/4/2008

More than 13,000 biological and biomedical scientists will gather for the Experimental Biology 2008 meeting in San Diego April 5-9.

The theme of the annual meeting, now in its 18th year, is Todays Research: Tomorrows Health. Thousands of lectures, symposia, research presentations and exhibits have been selected because of their potential to shape future and current clinical advances. Scientists and clinicians from dozens of different disciplines, from laboratory to translational to clinical research, from throughout the U.S. and the world, come together at Experimental Biology to discuss the newest scientific concepts and share the latest research findings with colleagues looking at similar biomedical problems through the lens of different disciplines.

The seven sponsoring societies for Experimental Biology 2008 are: American Association of Anatomists (AAA), The American Association of Immunologists (AAI), The American Physiological Society (APS), American Society for Biochemistry and Molecular Biology (ASBMB), American Society for Investigative Pathology (ASIP), American Society for Nutrition (ASN), and American Society for Pharmacology and Experimental Therapeutics (ASPET). Experimental Biology includes the annual meetings of all sponsoring societies.

Forty U.S. and international guest societies further broaden the scope of the meeting, adding scientists from fields such as biomedical engineering, behavioral pharmacology, veterinary pathology and immunology, biological and environmental repositories, and informatics, and from organizations such as the American College of Sports Medicine, American Diabetes Association, and American Heart Association.

The diversity of topics can be seen in this small sampling from the programs of sponsoring societies and their guests (all open to registered media):

Association of American Anatomists presentations range from an award lecture on links between essential self-prese
'/>"/>

Contact: Sylvia Wrobel
ebpress@gmail.com
770-722-1055
Federation of American Societies for Experimental Biology
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
11. Carnegie Mellon Establishes Ray and Stephanie Lane Center for Computational Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)... CosmetaLife clinical trial results could lea... ,cost-effective treatment for deep lines and wrin... Minn. (PRWEB) July 24, 2008 -- Gel-Del Technolog...e company announced that it has concluded clinical...that company officials say holds potential to be a...
(Date:7/24/2008)... The Palomino Group, a leading commercializat... announced the launch of its new Meeting Support S...tical industry. The company, based in Minneapolis,...ialization consulting services that support biotec... healthcare companies. , ...
(Date:7/24/2008).../PRNewswire-FirstCall/ --, Key Highlights, Misys...ions and is now,raising targets for the next phase...(1) of GBP492m up 6%, bringing Group operating pro... executing on its strategy and entering,into the n...orm for growth., To view the Multimedia News Rele...
(Date:7/23/2008)...ular Entities Drops to Historic Low as Pharma Comp...nerics Companies, LONDON, July 24 /PRNewswire/ --...announced the availability of the newly published ..., an indispensable reference,and business planning...orporate finance, business strategy, marketing pla...
Breaking Medicine News(10 mins):Health News:Clinical Trial Concluded For New Wrinkle Treatment 2Health News:Clinical Trial Concluded For New Wrinkle Treatment 3Health News:The Palomino Group Announces Launch of Meeting Support Services Business Unit 2Health News:The Palomino Group Announces Launch of Meeting Support Services Business Unit 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 2Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 4Health News:Thomson Reuters Publishes CMR International's 2008 Pharmaceutical R&D Factbook, Now Available for the First Time Online 2
...g blind and partially sighted people in the Lothia...e for the Blind (RNIB) received a ?25,000 donation...help in launching the charity's Positive Steps pro...ning for people preparing to enter employment. Th...
... for Type 2 Diabetes appears to have a twin benefi...ar under control// but also helps them to lose wei...n associate Professor with the Royal Prince Alfred...this drug has been under trial on patient voluntee...
... of teeth, do not improve the mental well being an...study//. Thousands of children have orthodontic wo...n the dental profession that braces or orthodontic...ll-being, reported the online edition of BBC News....
...cer deaths for the second consecutive year, the Am...can Health Challenge// to educate and motivate Ame... Many Americans are concerned about potentially d...t 50 percent of cancer deaths could be prevented t...
Other Medicine News:Health News:Healthy Behaviors Can Prevent at Least 50 Percent of Cancer Deaths 2
(Date:7/22/2008)...(R) Resulted in Significant, Reductions in A1C in ...thm Used, BRIDGE...the "Adjust to,Target in Type 2 Diabetes: Comparis...for Adjustment of Mealtime Insulin Glulisine" stud...tion,s (ADA) medical journal,Diabetes Care. This ...
(Date:7/22/2008)...wswire/ -- Hyperion,Therapeutics, Inc. today annou...ts Phase 1/2 clinical trial to evaluate the safety...PN-100 (formally called GT4P) versus,BUPHENYL(R) (... disorders,(UCD). The company plans to announce to..., (Logo: http://www.newscom.com/cgi-bin/prnh/200...
(Date:7/22/2008)...rsity Medical Center Based on Rosetta Ge...t Differentiates Squamous From Non-Squamous Non-Sm...s-Cell Carcinoma of the Lung With Sensitivi...s is the First CLIA Approved Test Which Leverages ...Accurate Diagnosis of Lung Cancer, REHOVOT, Israe...
(Date:7/22/2008)...ire-FirstCall/ -- NicOx S.A.,(Euronext Paris: COX)...,enrollment of 417 osteoarthritis (OA) patients wi...ology studies in the United States, in line with,p...signed to assess the,blood pressure profile of nap... using the Ambulatory Blood Pressure Monitoring (A...
Breaking Medicine Technology:Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Rheumatoid arthritis factors equal to cardiovascular factors in risk of severe cardiovascular events 21808 1Rheumatoid arthritis factors equal to cardiovascular factors in risk of severe cardiovascular events 21808 2Nanoparticles aid bone growth 21804 1Nanoparticles aid bone growth 21804 2Courage Center Extends Nomination Deadline for 2008 Phillips Awards to July 3 21800 1Courage Center Extends Nomination Deadline for 2008 Phillips Awards to July 3 21800 2Threatened or invasive 3F Species fates identified 3631 1Threatened or invasive 3F Species fates identified 3631 2
...Northfield,Laboratories Inc. (Nasdaq: NFLD) announ...has informed the Company that the report of,the su... with,PolyHeme(R), the Company,s human-hemoglobin ...t be complete until May., About Northfield Laborat...n developing an,oxygen-carrying red blood cell sub...
...tic,benefits of adding Diovan to conventional ther...mes for,Diovan patients , , , BASEL,Switzerlan...dent,Jikei Heart Study, published today in The Lan...ng medication Diovan® to,conventional therapy ...r events and a 40% reduction in stroke. , , The ...
Other Medicine Technology:Northfield Laboratories Investor Update 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7
The GENESIS II* Total Knee System will define the state of knee implants.
Cruciate Retaining, Posterior Stabilized and Constrained Components.
StelKast's Proven knee system is a long term, quality solution based on a clinically proven design. Available in both posterior stabilized and anatomically correct cruciate retaining configurations.
The Balanced Knee System provides instrumentation designed to achieve proper tissue balancing and alignment with user-friendly instrumentation that provides reproducible results.
Medicine Products: